Andrew Evens, DO, and Joanna Rhodes, MD, on CLL's transformation, CAR T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across New Jersey.
Andrew M. Evens, DO, MBA, MSc
Advertisement
Andrew Evens, DO, MBA, MSc, is the Deputy Director for Clinical Services and Chief Physician Officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center; System Director of Medical Oncology and Oncology Lead, RWJBarnabas Health Medical Group; and Associate Vice Chancellor for Clinical Innovation and Data Analytics, Rutgers Biomedical and Health Sciences.
Articles by Andrew M. Evens, DO, MBA, MSc
A new risk model uses objective clinical data to predict cure or relapse in Hodgkin lymphoma, with future plans to guide treatment and survivorship care.
Andrew Evens, DO, MBA, MSc, discusses a modern way of stratifying risk in patients with early-stage Hodgkin lymphoma.
Andrew Evens, DO, MBA, MSc, discusses the HOLISTIC consortium, which aims to gather and harmonize global Hodgkin lymphoma data from clinical trials and registries.
Andrew M. Evens, DO, MSc, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma were treated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine.
Advertisement
Latest Updated Articles
Lymphoma's Revolution: Evens & Rhodes on CLL, CAR T, and NJ CareAugust 21st 2026
Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHLDecember 3rd 2019
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
5